---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-25-000088"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:20:33.348770+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Senti Bio Q2 2025 net loss $14.7M; completes dose finding for SENTI-202 AML trial, RP2D confirmed

## Summary
- Net loss of $14.7M ($0.56 per share); cash $21.6M as of June 30, 2025, down from $48.3M at Dec 31, 2024.
- Completed dose finding and confirmed RP2D for Phase 1 SENTI-202 trial in AML; now in dose expansion.
- Received FDA Orphan Drug Designation for SENTI-202 in AML.
- Received $1.0M from CIRM grant; added Bryan Baum to Board, Dr. James Trager to Scientific Advisory Board.
- Expect additional efficacy and durability data from SENTI-202 Phase 1 study in Q4 2025.

## SEC filing metadata
- accession: 0001854270-25-000088
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/0001854270-25-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/snti-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-25-000088
- JSON: https://secwatch.observer/filing/0001854270-25-000088.json
- Plain text: https://secwatch.observer/filing/0001854270-25-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.